143 related articles for article (PubMed ID: 17673305)
41. HIV-1 protease inhibitors: effects on HIV-2 replication and resistance.
Menéndez-Arias L; Tözsér J
Trends Pharmacol Sci; 2008 Jan; 29(1):42-9. PubMed ID: 18054799
[TBL] [Abstract][Full Text] [Related]
42. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
Fox ZV; Geretti AM; Kjaer J; Dragsted UB; Phillips AN; Gerstoft J; Staszewski S; Clotet B; von Wyl V; Lundgren JD
AIDS; 2007 Oct; 21(15):2033-42. PubMed ID: 17885293
[TBL] [Abstract][Full Text] [Related]
43. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
[TBL] [Abstract][Full Text] [Related]
44. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
45. [New HIV-1 protease inhibitors in development].
Yoshimura K; Maeda K
Nihon Rinsho; 2002 Apr; 60(4):780-3. PubMed ID: 11968788
[TBL] [Abstract][Full Text] [Related]
46. Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.
Hill A; Walmsley S; Clotet B; Molto J
HIV Med; 2006 Mar; 7(2):67-74. PubMed ID: 16420251
[TBL] [Abstract][Full Text] [Related]
47. A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand.
Poonpiriya V; Sungkanuparph S; Leechanachai P; Pasomsub E; Watitpun C; Chunhakan S; Chantratita W
J Virol Methods; 2008 Jul; 151(1):79-86. PubMed ID: 18462814
[TBL] [Abstract][Full Text] [Related]
48. Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.
Di Giambenedetto S; Bacarelli A; Pinnetti C; Colafigli M; Prosperi M; Gatti G; Cauda R; De Luca A
Scand J Infect Dis; 2007; 39(9):813-8. PubMed ID: 17701721
[TBL] [Abstract][Full Text] [Related]
49. Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.
Cihlar T; He GX; Liu X; Chen JM; Hatada M; Swaminathan S; McDermott MJ; Yang ZY; Mulato AS; Chen X; Leavitt SA; Stray KM; Lee WA
J Mol Biol; 2006 Oct; 363(3):635-47. PubMed ID: 16979654
[TBL] [Abstract][Full Text] [Related]
50. Genetic mechanisms of resistance to protease inhibitors and entry inhibitors.
Soriano V; de Mendoza C
HIV Clin Trials; 2002; 3(3):249-57. PubMed ID: 12032884
[TBL] [Abstract][Full Text] [Related]
51. Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
Lu Z; Bohn J; Rano T; Rutkowski CA; Simcoe AL; Olsen DB; Schleif WA; Carella A; Gabryelski L; Jin L; Lin JH; Emini E; Chapman K; Tata JR
Bioorg Med Chem Lett; 2005 Dec; 15(23):5311-4. PubMed ID: 16203148
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.
Zhao C; Sham HL; Sun M; Stoll VS; Stewart KD; Lin S; Mo H; Vasavanonda S; Saldivar A; Park C; McDonald EJ; Marsh KC; Klein LL; Kempf DJ; Norbeck DW
Bioorg Med Chem Lett; 2005 Dec; 15(24):5499-503. PubMed ID: 16203141
[TBL] [Abstract][Full Text] [Related]
53. The intracellular pharmacology of antiretroviral protease inhibitors.
Ford J; Khoo SH; Back DJ
J Antimicrob Chemother; 2004 Dec; 54(6):982-90. PubMed ID: 15537695
[TBL] [Abstract][Full Text] [Related]
54. New class of inhibitor may attack resistance. Potential drug could be cost-efficient.
AIDS Alert; 2005 Jan; 20(1):6-7. PubMed ID: 15717354
[TBL] [Abstract][Full Text] [Related]
55. Cross-resistance patterns among HIV protease inhibitors.
Kozal M
AIDS Patient Care STDS; 2004 Apr; 18(4):199-208. PubMed ID: 15142350
[TBL] [Abstract][Full Text] [Related]
56. [New protease inhibitor atazanavir. Simple administration--less resistance].
MMW Fortschr Med; 2002 Aug; 144(31-32):47. PubMed ID: 12422733
[No Abstract] [Full Text] [Related]
57. Darunavir: a critical review of its properties, use and drug interactions.
Ruela Corrêa JC; D'Arcy DM; dos Reis Serra CH; Nunes Salgado HR
Pharmacology; 2012; 90(1-2):102-9. PubMed ID: 22797653
[TBL] [Abstract][Full Text] [Related]
58. Do the mutations M046I and I047A confer resistance to kaletra?
Price H; Jones R; Stevanovic M; Nelson M; Bower M; Mandalia S; Gazzard B
AIDS; 2006 Apr; 20(6):950-1. PubMed ID: 16549987
[No Abstract] [Full Text] [Related]
59. Rapid synthesis and in situ screening of potent HIV-1 protease dimerization inhibitors.
Lee SG; Chmielewski J
Chem Biol; 2006 Apr; 13(4):421-6. PubMed ID: 16632254
[TBL] [Abstract][Full Text] [Related]
60. HIV-1 protease inhibitors in development.
Rusconi S; La Seta Catamancio S
Expert Opin Investig Drugs; 2002 Mar; 11(3):387-95. PubMed ID: 11866667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
